GSK expands skin care portfolio
This article was originally published in The Tan Sheet
Consumer Healthcare division acquires five Rx topical dermatological products from Elan Pharmaceuticals, GSK announces Dec. 23. Firm will market Temovate, Emgel, Aclovate, Cutivate and Oxistat beginning Jan. 1, noting brands "are an excellent fit with" GSK's current OTC dermatology products Oxy (for acne)and Abreva (for cold sores). Firm expects "medical marketing expertise" gained from co-marketing Rx products such as Bactroban will add to success of acquisition. According to GSK, Elan reported the five products generated sales of $62 mil. in 2001...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.